International Journal of Drug Delivery Technology
Volume 14, Issue 2

Development of Inhaled Tuberculosis Microparticle using Polysaccharide Polymers Containing Rifamycin Groups: In-vitro and In-vivo Study

Finisha Prigestiya Dinanti1, Tristiana Erawati1, Dewi Melani Hariyadi1,2*

1Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Campus C Mulyorejo, Surabaya, Indonesia.

2Nanotechnology and Drug Delivery System Research Group, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Campus C Mulyorejo, Surabaya, Indonesia.

 Received: 09th April, 2023; Revised: 10th May, 2024; Accepted: 19th May, 2024; Available Online: 25th June, 2024 

ABSTRACT

Tuberculosis (TB) is one of the urgent global health problems. TB therapy involves the use of antibiotics, but unwanted side effects often accompany the treatment of TB with high doses and long periods of time. In an effort to increase the effectiveness of TB treatment and reduce side effects, direct drug delivery to the lungs is the focus of research. One of the approaches used is the development of drug delivery systems that use natural polymers in dry powder inhalation (DPI) formulations. Natural polymers, especially polysaccharides, have various advantages, such as biodegradability, biocompatibility and non-toxicity. This review discusses the use of rifamycin microparticle tuberculosis inhalation using polysaccharide polymers and reviews relevant in-vitro and in-vivo studies. The use of natural polymers, especially polysaccharides, is expected to increase the efficiency of TB therapy by reducing drug doses and systemic side effects and increasing direct drug delivery to infected organs.

Keywords: Rifamycin, Inhalation, Natural polymer, Microparticle, In-vivo.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.77

How to cite this article: Dinanti FP, Erawati T, Hariyadi DM.. Development of Inhaled Tuberculosis Microparticle using Polysaccharide Polymers Containing Rifamycin Groups: In-vitro and In-vivo Study. International Journal of Drug Delivery Technology. 2024;14(2):1116-1123.

REFERENCES

  1. Bagcchi S. WHO’s global tuberculosis report 2022. The Lancet 2023;4(1): e20. Available from: doi.org/ 10.1016/S2666- 5247(22)00359-7
  2. Rothstein DM. Rifamycins, alone and in combination. Cold Spring Harbor Perspectives in Medicine. 2016;6(7). Available from: doi.org/10.1101/cshperspect.a027011
  3. Adams RA, Leon G, Miller NM, Reyes SP, Thantrong CH, Thokkadam AM, et Rifamycin antibiotics and the mechanisms of their failure. Journal of Antibiotics. 2021; 786–798. Available from: doi.org/10.1038/s41429-021-00462-x
  4. Khadka P, Dummer J, Hill PC, Das SC. Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment. International Journal of Pharmaceutics. 2018;548(1): 244 –254. Available from: org/10.1016/j.pharm.2018.07.011
  5. Knap K, Kwiecień K, Reczyńska-Kolman K, Pamuła Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations. Regenerative Biomaterials. 2023;10, rbac099. Available from: doi.org/10.1093/rb/rbac099
  6. Naz FF, Shah KU, Niazi ZR, Zaman M, Lim V, Alfatama M. Polymeric Microparticles: Synthesis, Characterization and In Vitro Evaluation for Pulmonary Delivery of Rifampicin. Polymers. 2022;14(12):2491. Available from: doi.org/10.3390/ polym14122491
  7. Rosita N, Kalalo T, Miatmoko A, Pathak Y, Hariyadi D. Microspheres for Inhalation Delivery (Characteristics and In Vitro Release). International Journal of Medical Reviews and Case Reports. 2022;(62):24-31. Available from: doi.org/10.5455/ ijmrcr.microspheresforinhalationdelivery
  8. Racovita S, Vasiliu S, Popa M, Asachi G, Luca Polysaccharide based on micro-and nanoparticles obtained by ionic gelation and their applications as drug delivery systems. Revue Roumaine de Chimie. 2009; 54(9):709-718. https://www.researchgate.net/ publication/228471533
  9. Hariyadi DM, Purwanti T, Kusumawati I, Nirmala RN, Maindra HMC. Physical Characterization and In Vivo Study of Ovalbumin Encapsulated in Alginate Microspheres. Available online on International Journal of Drug Delivery Technology. 2015;5(2): 48–53. https://impactfactor.org/PDF/IJDDT/5/ IJDDT,Vol5,Issue2,Article2.pdf
  10. Esposito E, Cortesi R, Luca G, Nastruzzi C. Pectin-Based Microspheres A Preformulatory Annals of the New York Academy of Sciences. 2001;944: 160–179.
  11. Jedvert K, Heinze T. Cellulose modification and shaping - A review. Journal of Polymer Engineering. 2017;37(9): 845–860. Available from: doi.org/10.1515/polyeng-2016-0272
  12. Kumar A, Rao KM, Han SS. Application of xanthan gum as polysaccharide in tissue engineering: A review. Carbohydrate 2018;180:128–144. Available from: doi.org/10.1016/j. carbpol.2017.10.009
  13. Patil JS, Kamalapur M V, Marapur SC, Kadam D Ionotropic gelation and polyelectrolyte complexation: The novel techniques to design hydrogel particulate sustained, modulated drug delivery system: A review. Digest Journal of Nanomaterials and Biostructures. 2010;5(1):241-248. https://www.chalcogen. ro/241_Patil.pdf
  14. Cunha L, Rodrigues S, da Costa AMR, Faleiro ML, Buttini F, Grenha A. Inhalable fucoidan microparticles combining two antitubercular drugs with potential application in pulmonary tuberculosis Polymers. 2018;10(6):636. Available from: doi.org/10.3390/polym10060636
  15. Sun Y, Xu X, Zhang Q, Zhang D, Xie X, Zhou H, Wu Z, Liu R, Pang J. Review of Konjac Glucomannan Structure, Properties, Gelation Mechanism, and Application in Medical Biology. Polymers. 2023;15(8):1852. Available from: doi.org/10.3390/ polym15081852
  16. Guerreiro F, Pontes JF, Rosa da Costa AM, Grenha A. Spray- drying of konjac glucomannan to produce microparticles for an application as antitubercular drug Powder Technology. 2019;342: 246 –252. Available from: doi.org/10.1016/j. powtec.2018.09.068
  17. Alves AD, Cavaco JS, Guerreiro F, Lourenço JP, Rosa Da Costa AM, Grenha A. Inhalable antitubercular therapy mediated by locust bean gum Molecules. 2016;21(6):702. Available from: doi.org/10.3390/molecules21060702
  18. Prajapati VD, Jani GK, Moradiya NG, Randeria NP, Maheriya PM, Nagar BJ. Locust bean gum in the development of sustained release mucoadhesive macromolecules of Carbohydrate Polymers. 2014;113: 138–148. Available from: doi. org/10.1016/j.carbpol.2014.06.061
  19. Purwanti T, Satriawan RA, Hariyadi DM. The effect of the comparison of sodium alginate-gelatin levels on microspheres characteristics (Produced by ionic gelation method aerosolized technique). International Journal of Drug Delivery Technology. 2020;10(2): 301–306. Available from: doi.org/10.25258/ 10.2.19
  20. Lebrun P, Krier F, Mantanus J, Grohganz H, Yang M, Rozet E, et al. Design space approach in the optimization of the spray-drying process. European Journal of Pharmaceutics and Biopharmaceutics. 2012;80(1): 226–234. Available from: doi. org/10.1016/j.ejpb.2011.09.014
  21. Alhajj N, O’Reilly NJ, Cathcart Quality by design – Spray drying of ciprofloxacin-quercetin fixed-dose combination intended for inhalation. International Journal of Pharmaceutics. 2023;642: 123151. Available from: doi.org/10.1016/j.ijpharm.2023.123151
  22. Khadka P, Dummer J, Hill PC, Das SC. Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment. International Journal of Pharmaceutics. 2018;548(1): 244 –254. Available from: doi.org/10.1016/j. 2018.07.011
  23. Hariyadi DM, Hendradi E, Pratama HE, Rahmadi Microspheres as pulmonary delivery systems - A review. Journal of Chinese Pharmaceutical Sciences. 2021;30(7): 545–555. Available from: doi.org/10.5246/jcps.2021.07.043
  24. Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and Journal of Antimicrobial Chemotherapy. 2005; 55(4):430-435. Available from: doi. org/10.1093/jac/dki027
  25. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder Respiratory care. 2005;50(10): 1313–1322.
  26. Ferguson GT, Hickey AJ, Dwivedi S. Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respiratory Medicine. 2018; 134:16-23. Available from: doi.org/10.1016/j. 2017.09.012
  27. Mitnick CD, Mc Gee B, Peloquin Tuberculosis pharmacotherapy: Strategies to optimize patient care. Expert Opinion on Pharmacotherapy. 2009;10(3):381-401. Available from: doi.org/10.1517/14656560802694564
  28. Parikh R, Patel L, Dalwadi S. Microparticles of rifampicin: Comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Delivery. 2014;21(6): 406–411. Available from: doi.org/10.3109/10717544.2013.851302
  29. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. International Journal of Pharmaceutics. 2004;269(1): 37– Available from: doi.org/10.1016/j. ijpharm.2003.08.017
  30. Pham DD, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. International journal of pharmaceutics. 2015;478(2): 517–529. Available from: doi. org/10.1016/j.ijpharm.2014.12.009
  31. Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. Journal of Antimicrobial Chemotherapy. 2008;62(5): 872–878. Available from: doi. org/10.1093/jac/dkn330
  32. Valverde-Fraga L, Haddad R, Alrabadi N, Sánchez S, Remuñán- López C, Csaba N. Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin. European Journal of Pharmaceutical 2023;187: 106484. Available from: doi.org/10.1016/j.ejps.2023.106484
  33. Chan JGY, Bai X, Traini An update on the use of rifapentine for tuberculosis therapy. Expert Opinion on Drug Delivery. 2014;11(3):421-431. Available from: doi.org/10.1517/17425247.2 014.877886
  34. Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, et al. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Science Translational Medicine. 2018;10(435) :eaai7786. Available from: doi.org/10.1126/scitranslmed.aai7786
  35. Sekaggya-Wiltshire C, Dooley KE. Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opinion on Drug Metabolism and Toxicology. 2019; 15(8):615–618. Available from: doi.org/1 0.1080/17425255.2019.1648432
  36. Prestisya I, Miatmoko A, Rahmadi M, Hariyadi Dry powder inhalation microparticles (alginate, carrageenan, chitosan, and combination polymers): a review on characteristics and in vivo activity. Egyptian Journal of Chemistry. 2022;65(12): 181–206. Available from: doi.org/10.21608/EJCHEM.2022.119143.5364
  37. Putri KSS, Ramadhani LS, Rachel T, Suhariyono G, Surini S. Promising chitosan-alginate combination for rifampicin dry powder inhaler to target active and latent Journal of Applied Pharmaceutical Science. 2022;12(5): 098–103. Available from: doi.org/10.7324/JAPS.2022.120507
  38. Rawal T, Parmar R, Tyagi RK, Butani S. Rifampicin loaded chitosan nanoparticle dry powder presents: An improved therapeutic approach for alveolar tuberculosis. Colloids and Surfaces B: Biointerfaces. 2017;154: 321–330. Available from: doi.org/10.1016/j.colsurf 2017.03.044
  39. Scolari IR, Páez PL, Sánchez-Borzone ME, Granero GE. Promising Chitosan-Coated Alginate-Tween 80 Nanoparticles as Rifampicin Coadministered Ascorbic Acid Delivery Carrier Against Mycobacterium tuberculosis. AAPS PharmSciTech. 2019;20(2). Available from: doi.org/10.1208/s12249-018-1278-7
  40. Pai R V., Jain RR, Bannalikar AS, Menon MD. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin. Journal of Aerosol Medicine and Pulmonary Drug 2016;29(2): 179–195. Available from: doi.org/10.1089/jamp.2014.1187
  41. Manca ML, Valenti D, Sales OD, Nacher A, Fadda AM, Manconi Fabrication of polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of rifampicin. International Journal of Pharmaceutics. 2014;472(1–2): 102–109. Available from: doi.org/10.1016/j.ijpharm.2014.06.009
  42. S JP, Devi K, Devi K, Suresh S. Formulation and Evaluation of Novel Spray-dried Alginate Microspheres as Pulmonary Delivery Systems of Rifampicin in Indian Journal of Pharmaceutical Education and Research. 2015;49(4): 320–328. Available from: doi.org/10.5530/ijper.49.4.9
  43. Rawal T, Kremer L, Halloum I, Butani S. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2017;30(6): 388–398. Available from: doi.org/10.1089/jamp.2017.1379
  44. Kundawala A, Patel V, Patel H, Choudhary D. Preparation, In vitro characterization, And in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin. Scientia Pharmaceutica. 2014;82(3): 665–681. Available from: org/10.3797/scipharm.1307-03
  45. Goyal AK, Garg T, Rath G, Gupta UD, Gupta P. Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Molecular Pharmaceutics. 2015;12(11): 3839–3850. Available from: doi.org/10.1021/acs. molpharmaceut.5b00016
  46. Rodrigues S, Grenha A. Activation of macrophages: Establishing a role for polysaccharides in drug delivery strategies envisaging antibacterial therapy. Current pharmaceutical design. 2015;21(33): 4869–4887. Available from: org/10.2174/1381612821666150 820103910
  47. Guerreiro F, Swedrowska M, Patel R, Flórez-Fernández N, Torres MD, Rosa da Costa AM, Forbes B, & Grenha A. Engineering of konjac glucomannan into respirable microparticles for delivery of antitubercular drugs. International journal of 2021;604: 120731. Available from: doi. org/10.1016/j.ijpharm.2021.120731.
  48. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, & Nuermberger Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS medicine. 2007;4(12): e344. Available from: doi.org/10.1371/journal. pmed.0040344
  49. Clemens DL, Lee BY, Xue M, Thomas CR, Meng H, Ferris D, Nel AE, Zink JI, & Horwitz Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. Antimicrobial Agents and Chemotherapy. 2012;56(5): 2535–2545. Available from: doi.org/10.1128/AAC.06049-11